| Literature DB >> 29376889 |
Evelyn Ullrich1,2,3, Benjamin Abendroth4, Johanna Rothamer1,2,3, Carina Huber4, Maike Büttner-Herold5, Vera Buchele4, Tina Vogler4, Thomas Longerich6, Sebastian Zundler4, Simon Völkl1, Andreas Beilhack7, Stefan Rose-John8, Stefan Wirtz4, Georg F Weber9, Sakhila Ghimire10, Marina Kreutz10, Ernst Holler10, Andreas Mackensen1, Markus F Neurath4, Kai Hildner4.
Abstract
Acute graft-versus-host disease (GVHD) represents a severe, T cell-driven inflammatory complication following allogeneic hematopoietic cell transplantation (allo-HCT). GVHD often affects the intestine and is associated with a poor prognosis. Although frequently detectable, proinflammatory mechanisms exerted by intestinal tissue-infiltrating Th cell subsets remain to be fully elucidated. Here, we show that the Th17-defining transcription factor basic leucine zipper transcription factor ATF-like (BATF) was strongly regulated across human and mouse intestinal GVHD tissues. Studies in complete MHC-mismatched and minor histocompatibility-mismatched (miHA-mismatched) GVHD models revealed that BATF-expressing T cells were functionally indispensable for intestinal GVHD manifestation. Mechanistically, BATF controlled the formation of colon-infiltrating, IL-7 receptor-positive (IL-7R+), granulocyte-macrophage colony-stimulating factor-positive (GM-CSF+), donor T effector memory (Tem) cells. This T cell subset was sufficient to promote intestinal GVHD, while its occurrence was largely dependent on T cell-intrinsic BATF expression, required IL-7-IL-7R interaction, and was enhanced by GM-CSF. Thus, this study identifies BATF-dependent pathogenic GM-CSF+ effector T cells as critical promoters of intestinal inflammation in GVHD and hence putatively provides mechanistic insight into inflammatory processes previously assumed to be selectively Th17 driven.Entities:
Keywords: Bone marrow transplantation; Cytokines; Gastroenterology; Immunology; T cells
Mesh:
Substances:
Year: 2018 PMID: 29376889 PMCID: PMC5824870 DOI: 10.1172/JCI89242
Source DB: PubMed Journal: J Clin Invest ISSN: 0021-9738 Impact factor: 14.808